[Preliminary evaluation of the effect of ibopamine on the secretion of prolactin].

Ibopamine, diisobutyric ester of N-methyl dopamine, is an orally active dopaminergic agonist. The prolactin-lowering activity of Ibopamine was studied in 8 subjects with normal prolactine levels given the drug in a single dose of 100 mg. Prolactin levels measured by radioimmuno assay were evaluated before and within 2, 4 and 8 h of administration.

Effectiveness of ibopamine in the management of ascitic liver cirrhosis--a controlled study v placebo and frusemide.

1 Thirty in-patients of both sexes suffering from ascitic liver cirrhosis were divided into three groups treated with (a) a placebo, (b) ibopamine (SB 7505, a new oral dopaminergic drug) and (c) frusemide, for 10 days. 2 Body weight decreased with both frusemide and ibopamine, diuresis and urinary excretion of Na+ and Cl- increased with both drugs; whereas urinary excretion of K+ increased only with frusemide. 3 An important difference between the frusemide and ibopamine treatment was encountered in creatinine clearance, which increased only with ibopamine, and in blood uric acid which increased only with frusemide.